keyword
https://read.qxmd.com/read/38503602/theranostics-of-thyroid-cancer
#1
REVIEW
Luca Giovanella, Murat Tuncel, Atena Aghaee, Alfredo Campenni, Petra Petranović Ovčariček, Armando De Virgilio
Molecular imaging is pivotal in evaluating and managing patients with different thyroid cancer histotypes. The existing, pathology-based, risk stratification systems can be usefully refined, by incorporating tumor-specific molecular and molecular imaging biomarkers with theranostic value, allowing patient-specific treatment decisions. Molecular imaging with different radioactive iodine isotopes (ie, I131 , I123 , I124 ) is a central component of differentiated carcinoma (DTC)'s risk stratification while [18 F]F-fluorodeoxyglucose ([18 F]FDG) PET/CT is interrogated about disease aggressiveness and presence of distant metastases...
March 18, 2024: Seminars in Nuclear Medicine
https://read.qxmd.com/read/38501238/survival-predictors-of-radioiodine-refractory-differentiated-thyroid-cancer-treated-with-lenvatinib-in-the-real-life
#2
JOURNAL ARTICLE
Vincenzo Marotta, Domenico Rocco, Anna Crocco, Maria Grazia Deiana, Ruggero Martinelli, Francesca Di Gennaro, Mariafelicia Valeriani, Luca Valvano, Alessia Caleo, Luciano Pezzullo, Antongiulio Faggiano, Mario Vitale, Salvatore Monti
CONTEXT: Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). The definition of predictive factors of survival is incomplete. OBJECTIVE: To identify pre- and post- treatment survival predictors in a real-life cohort of RR-DTC treated with lenvatinib. DESIGN: Multicenter, retrospective, cohort study. SETTING: Three Italian thyroid cancer referral centers. PARTECIPANTS: 55 RR-DTC treated with lenvatinib...
March 19, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38464386/recent-preclinical-and-clinical-advances-in-radioimmunotherapy-for-non-hodgkin-s-lymphoma
#3
REVIEW
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada
Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventional treatment. The purpose of this review is to summarize the current progress of RIT for treating non-Hodgkin's lymphoma (NHL) based on recent preclinical and clinical studies. The efficacy of RIT targeting the B-lymphocyte antigen cluster of differentiation 20 (CD20) has been demonstrated in clinical trials. Two radioimmunoconjugates targeting CD20, yttrium-90 (90 Y)-ibritumomab-tiuxetan (Zevalin) and iodine-131 (131 I)-tositumomab (Bexxar), have been approved in the USA Food and Drug Administration (FDA) for treating relapsed/refractory indolent or transformed NHL in 2002 and 2003, respectively...
2024: Exploration of targeted anti-tumor therapy
https://read.qxmd.com/read/38455372/risk-stratification-for-radioactive-iodine-refractoriness-using-molecular-alterations-in-distant-metastatic-differentiated-thyroid-cancer
#4
JOURNAL ARTICLE
Zhuanzhuan Mu, Xin Zhang, Dongquan Liang, Jugao Fang, Ge Chen, Wenting Guo, Di Sun, Yuqing Sun, Zhentian Kai, Lisha Huang, Jun Liang, Yansong Lin
OBJECTIVE: Patients with radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) are often diagnosed with delay and constrained to limited treatment options. The correlation between RAI refractoriness and the underlying genetic characteristics has not been extensively studied. METHODS: Adult patients with distant metastatic DTC were enrolled and assigned to undergo next-generation sequencing of a customized 26-gene panel (ThyroLead). Patients were classified into RAIR-DTC or non-RAIR groups to determine the differences in clinicopathological and molecular characteristics...
February 29, 2024: Chinese Journal of Cancer Research
https://read.qxmd.com/read/38452309/an-era-of-advances-in-systemic-therapies-for-advanced-thyroid-cancer
#5
REVIEW
Karen M Yun, Ezra E W Cohen
Thyroid carcinomas comprise distinct pathologic subtypes. However, advancements in characterizing the molecular tumorigenesis of thyroid cancers have changed the treatment paradigm in the past decade. Genetic profiling has become an integral component of personalizing cancer care. Oral kinase inhibitors are currently standard-of-care therapies for progressive, radioactive iodine (RAI)-refractory differentiated thyroid carcinomas (DTCs) and medullary thyroid carcinomas (MTCs). Sorafenib, lenvatinib, and cabozantinib are multikinase inhibitors approved for patients with metastatic RAI-refractory DTC, whereas vandetanib and cabozantinib are approved for patients with MTC...
March 7, 2024: JCO oncology practice
https://read.qxmd.com/read/38447630/early-structural-biochemical-and-metabolic-response-to-anlotinib-in-patients-with-progressive-radioactive-iodine-refractory-differentiated-thyroid-cancer
#6
JOURNAL ARTICLE
Di Sun, Xin Zhang, Yuqing Sun, Zhuanzhuan Mu, Hao Wang, Yingqiang Zhang, Jun Liang, Yansong Lin
OBJECTIVE: We aimed to assess the early efficacy of anlotinib in progressive radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) patients in terms of structural, biochemical, and metabolic levels. METHODS: Ten eligible patients were prospectively enrolled to receive anlotinib. Six weeks' response were assessed. Apart from the structural response according to RECIST 1.1, biochemical response was assessed by serum thyroglobulin (Tg), metabolic response was assessed by 18 F-FDG PET/CT according to the EORTC criteria...
March 4, 2024: Endocrine Practice
https://read.qxmd.com/read/38427812/differentiated-thyroid-carcinoma-what-the-nonspecialists-needs-to-know
#7
REVIEW
Ana O Hoff, Aline Lauda Freitas Chaves, Thiago Bueno de Oliveira, Helton Estrela Ramos, Gustavo Cancela Penna, Lucas Vieira Dos Santos, Ana Luiza Maia, Daniel Oliveira Brito, Franco Pelissari Vizzotto
Differentiated thyroid carcinoma (DTC) accounts for most cases of thyroid cancer, and the heterogeneity of DTC requires that management decisions be taken by a multidisciplinary team involving endocrinologists, head and neck surgeons, nuclear medicine physicians, pathologists, radiologists, radiation oncologists, and medical oncologists. It is important for nonspecialists to recognize and refer patients with DTC who will benefit from a specialized approach. Recent advances in knowledge and changes in management of DTC call for the need to raise awareness on the part of these nonspecialist physicians, including general endocrinologists and medical oncologists at large...
February 29, 2024: Archives of Endocrinology and Metabolism
https://read.qxmd.com/read/38411874/utility-and-optimal-management-of-planned-drug-holidays-during-lenvatinib-treatment-in-patients-with-unresectable-differentiated-thyroid-cancer-a-real-world-multi-center-study
#8
JOURNAL ARTICLE
Takuya Mikoshiba, Mariko Sekimizu, Takeyuki Kono, Ryoto Nagai, Taiji Kawasaki, Yoichiro Sato, Fumihiro Ito, Nana Nakahara, Seiji Shigetomi, Hiroyuki Ozawa
PURPOSE: Lenvatinib achieves favorable therapeutic outcomes for patients with radioactive iodine therapy refractory differentiated thyroid cancer (DTC); however, its use is associated with a high incidence of adverse events. To avoid severe adverse events, planned drug holidays (PDH) have been proposed. This study aimed to evaluate treatment effects, identify prognostic factors, and investigate the usefulness of PDH in patients with unresectable DTC who received lenvatinib across the multi-institutions...
February 27, 2024: Endocrine
https://read.qxmd.com/read/38349206/clinical-and-histopathological-risk-factors-for-radioactive-iodine-refractory-follicular-and-oncocytic-thyroid-carcinoma
#9
JOURNAL ARTICLE
Merel T Stegenga, Evert F S van Velsen, Lindsey Oudijk, Frederik A Verburg, Tessa M van Ginhoven, Robin P Peeters, Marco Medici, W Edward Visser, Folkert J van Kemenade
INTRODUCTION: Risk factors for radioactive iodine (RAI)-refractory disease in follicular (FTC) and oncocytic thyroid carcinoma (OTC) are unknown. Therefore, the aim of this study is to identify clinical and histopathological risk factors for RAI-refractory disease in FTC and OTC patients, facilitated by an extensive histopathological revision. METHODS: All adult FTC and OTC patients treated at Erasmus MC (the Netherlands) between 2000 and 2016 were retrospectively included...
February 13, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38320311/two-synchronous-paraneoplastic-endocrine-syndromes-in-a-53-year-old-male-with-broadly-metastatic-widely-invasive-h%C3%A3-rthle-cell-carcinoma
#10
JOURNAL ARTICLE
John J Orrego, Joseph A Chorny
SUMMARY: Unlike medullary thyroid carcinomas, follicular cell-derived thyroid malignancies have rarely been associated with paraneoplastic endocrine syndromes. An ultrarare case of a middle-aged man with heavily treated broadly metastatic radioactive iodine-refractory widely invasive Hürthle cell carcinoma (HCC) of the thyroid with two synchronous paraneoplastic endocrine syndromes, T3 thyrotoxicosis and hypercalcemia of malignancy, is discussed here. The levothyroxine-induced T3 thyrotoxicosis was a gradual process that became more noticeable as the tumor burden, refractory to different modalities of therapy, expanded...
January 1, 2024: Endocrinology, Diabetes & Metabolism Case Reports
https://read.qxmd.com/read/38283726/long-term-treatment-of-pediatric-metastatic-papillary-thyroid-cancer-with-lenvatinib
#11
Julia R Donner, Bradley DeNardo, Lisa Swartz Topor
Papillary thyroid carcinoma (PTC) is the most common pediatric thyroid malignancy and incidence is increasing. Standard treatment for PTC in pediatric patients includes surgical intervention, suppression of TSH with levothyroxine, and radioactive iodine therapy (RAI) in select patients. In the setting of metastatic PTC or PTC refractory to RAI therapy, tyrosine kinase inhibitors (TKIs), such as lenvatinib, may be used. Until recently, experience with these targeted agents were largely limited to adult patients with progressive or refractory PTC...
February 2024: JCEM Case Rep
https://read.qxmd.com/read/38255638/tyrosine-kinase-inhibitors-for-radioactive-iodine-refractory-differentiated-thyroid-cancer
#12
REVIEW
Christos Cortas, Haris Charalambous
Patients with differentiated thyroid cancer usually present with early-stage disease and undergo surgery followed by adjuvant radioactive iodine ablation, resulting in excellent clinical outcomes and prognosis. However, a minority of patients relapse with metastatic disease, and eventually develop radioactive iodine refractory disease (RAIR). In the past there were limited and ineffective options for systemic therapy for RAIR, but over the last ten to fifteen years the emergence of tyrosine kinase inhibitors (TKIs) has provided important new avenues of treatment for these patients, that are the focus of this review...
December 22, 2023: Life
https://read.qxmd.com/read/38128440/clinicopathological-features-of-differentiated-thyroid-carcinoma-as-predictors-of-the-effects-of-radioactive-iodine-therapy
#13
JOURNAL ARTICLE
Wen Liu, Beibei Jiang, Jingli Xue, Ruijing Liu, Yuqing Wei, Peifeng Li
BACKGROUND: Patients with differentiated thyroid cancer (DTC) usually have an excellent prognosis; however, 5 %-15 % develop radioactive iodine-refractory (RAIR) DTC (RAIR-DTC), which has a poor prognosis and limited treatment options. The aim of the present study was to investigate the clinicopathological characteristics of RAIR-DTC in order to provide clinical evidence for timely prediction of the effects of iodine therapy. METHODS: Clinicopathological data for 44 patients with RAIR-DTC and 50 patients with radioiodine-avid DTC (RAIA-DTC) were retrospectively analyzed...
December 12, 2023: Annals of Diagnostic Pathology
https://read.qxmd.com/read/38096102/real-world-practice-patterns-and-outcomes-for-rai-refractory-differentiated-thyroid-cancer
#14
JOURNAL ARTICLE
Andrew G Gianoukakis, Jennifer H Choe, Daniel W Bowles, Marcia S Brose, Lori Wirth, Taofeek Owonikoko, Svetlana Babajanyan, Francis P Worden
BACKGROUND: The optimal timing for initiating multi-kinase inhibitors (MKIs) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC) remains unclear. Thus, we evaluated the real-world practice patterns and outcomes in asymptomatic patients with progressive RAI-R DTC (≥1 lesion ≥1 cm in diameter) in the United States (US) and outside the US (non-US). METHODS: In this prospective, non-interventional, open-label study, eligible patients were chosen by treating physicians to receive MKI therapy (Cohort 1) or undergo active surveillance (Cohort 2) at study entry...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/38060243/characterizing-genetic-alterations-related-to-radioiodine-avidity-in-metastatic-thyroid-cancer
#15
JOURNAL ARTICLE
Zhuanzhuan Mu, Xin Zhang, Di Sun, Yuqing Sun, Cong Shi, Gaoda Ju, Zhentian Kai, Lisha Huang, Libo Chen, Jun Liang, Yansong Lin
CONTEXT: Patients with distant metastatic DTC (DM-DTC) usually failed to be recognized as radioactive iodine (RAI)-refractory DTC timely. The elucidation of genetic features related to RAI uptake patterns may shed light on the early recognition of RAI-refractory DTC. OBJECTIVE: This work aimed to elucidate the underlying molecular features behind different RAI uptake patterns. METHODS: A total of 214 patients with DM-DTC were retrospectively included in the analysis...
December 7, 2023: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38044137/the-frequency-of-mutations-in-advanced-thyroid-cancer-in-japan-a-single-center-study
#16
JOURNAL ARTICLE
Soji Toda, Hiroyuki Iwasaki, Yoichiro Okubo, Hiroyuki Hayashi, Mei Kadoya, Hiroyuki Takahashi, Tomoyuki Yokose, Yukihiko Hiroshima, Katsuhiko Masudo
We analyzed the outcomes of genetic testing to study the frequency of mutations in advanced thyroid cancer in Japan. Patients (n = 96) with unresectable or metastatic thyroid carcinoma were included for retrospective chart review. Results of gene panel testing, which was performed between May 2020 and April 2023, were analyzed. The median age of the patients was 73.5 years (range, 17-88); 59 were women, and 39 were men. Overall, 17 patients had anaplastic thyroid carcinoma (ATC), 68 had papillary thyroid carcinoma (PTC), 7 had follicular thyroid carcinoma, and 6 had poorly differentiated thyroid carcinoma (PDTC)...
December 1, 2023: Endocrine Journal
https://read.qxmd.com/read/38041877/radioiodine-refractory-differentiated%C3%A2-thyroid-cancer-molecular-mechanisms-and-therapeutic-strategies-for-radioiodine-resistance
#17
REVIEW
Huize Shen, Rui Zhu, Yanyang Liu, Yangjian Hong, Jiaming Ge, Jie Xuan, Wenyuan Niu, Xuefei Yu, Jiang-Jiang Qin, Qinglin Li
Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) is difficult to treat with radioactive iodine because of the absence of the sodium iodide transporter in the basement membrane of thyroid follicular cells for iodine uptake. This is usually due to the mutation or rearrangement of genes and the aberrant activation of signal pathways, which result in abnormal expression of thyroid-specific genes, leading to resistance of differentiated thyroid cancer cells to radioiodine therapy. Therefore, inhibiting the proliferation and growth of RAIR-DTC with multikinase inhibitors and other drugs or restoring its differentiation and then carrying out radioiodine therapy have become the first-line treatment strategies and main research directions...
January 2024: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://read.qxmd.com/read/38028246/posterior-reversible-encephalopathy-syndrome-as-an-adverse-effect-of-lenvatinib-in-a-patient-with-papillary-thyroid-carcinoma-a-case-report
#18
Daisy Carolina Buenaventura, Hernando Vargas-Sierra, Natalia Aristizabal-Henao, Jose Luis Torres-Grajales, Carolina Aguilar-Londono, Johnayro Gutierrez-Restrepo
Posterior reversible encephalopathy syndrome (PRES) is an uncommon transient neuroradiological phenomenon that develops vasogenic cerebral edema and could be caused by some pharmacological agents, such as molecular-specific target agents. Lenvatinib belongs to the tyrosine kinase inhibitors and was approved in 2015 for progressive locally advanced or metastatic thyroid cancer refractory to radioactive iodine (I-131) treatment. Herein, we present the case of a 65-year-old woman who, while receiving treatment with lenvatinib for radioiodine-refractory metastatic papillary thyroid carcinoma, developed PRES without hypertension at the initial evaluation...
July 2023: International Journal of Endocrinology and Metabolism
https://read.qxmd.com/read/38009335/lymph-node-imaging-for-thyroid-cancer
#19
REVIEW
Simon A Holoubek, Rebecca S Sippel
Cervical lymph nodes (LNs) in the central (level VI) and lateral (levels II-V) compartments of the neck are the most common sites of locoregional metastases associated with thyroid cancer. Prophylactic nodal dissections are uncommon in modern thyroid surgery and are not routinely performed due to concern for increased morbidity and do not offer improved survival. Therefore, a selective approach for LN dissections is increasingly important. Preoperatively, this is most frequently assessed with cervical ultrasound (US)...
November 27, 2023: Clinical Endocrinology
https://read.qxmd.com/read/38002329/lenvatinib-loaded-poly-lactic-co-glycolic-acid-nanoparticles-with-epidermal-growth-factor-receptor-antibody-conjugation-as-a-preclinical-approach-to-therapeutically-improve-thyroid-cancer-with-aggressive-behavior
#20
JOURNAL ARTICLE
Giovanna Revilla, Nuseibah Al Qtaish, Pablo Caruana, Myriam Sainz-Ramos, Tania Lopez-Mendez, Francisco Rodriguez, Verónica Paez-Espinosa, Changda Li, Núria Fucui Vallverdú, Maria Edwards, Antonio Moral, José Ignacio Pérez, Juan Carlos Escolà-Gil, José Luis Pedraz, Idoia Gallego, Rosa Corcoy, María Virtudes Céspedes, Gustavo Puras, Eugènia Mato
BACKGROUND: Lenvatinib, a tyrosine kinase inhibitor (TKI) approved for the treatment of progressive and radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), is associated with significant adverse effects that can be partially mitigated through the development of novel drug formulations. The utilization of nanoparticles presents a viable option, as it allows for targeted drug delivery, reducing certain side effects and enhancing the overall quality of life for patients...
November 13, 2023: Biomolecules
keyword
keyword
117482
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.